APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

RNA-based Biopharmaceuticals

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global RNA-based Biopharmaceuticals Market Analysis and Forecast 2026-2032

Report ID 174033270221 December 2025202 pages

Choose your research edition.

Industry ResearchRNA-based Biopharmaceuticals Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal RNA-based Biopharmaceuticals Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal RNA-based Biopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal RNA-based Biopharmaceuticals Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal RNA-based Biopharmaceuticals Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global RNA-based Biopharmaceuticals market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for RNA-based Biopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for RNA-based Biopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for RNA-based Biopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for RNA-based Biopharmaceuticals is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of RNA-based Biopharmaceuticals include Roche, Pfizer, Tekmira, Silenseed, Silence Therapeutics, Senesco, Sanofi-Aventis, RXi and Quark, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for RNA-based Biopharmaceuticals, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of RNA-based Biopharmaceuticals, also provides the sales of main regions and countries. Of the upcoming market potential for RNA-based Biopharmaceuticals, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the RNA-based Biopharmaceuticals sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global RNA-based Biopharmaceuticals market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for RNA-based Biopharmaceuticals sales, projected growth trends, production technology, application and end-user industry.

RNA-based Biopharmaceuticals Segment by Company

Roche

Pfizer

Tekmira

Silenseed

Silence Therapeutics

Senesco

Sanofi-Aventis

RXi

Quark

Gradalis

Dicerna

Calimmune Inc

Benitec Biopharma

Arrowhead Pharmaceuticals

Alnylam Pharmaceuticals

Abbott Laboratories

RNA-based Biopharmaceuticals Segment by Type

Therapeutics

Vaccines

RNA-based Biopharmaceuticals Segment by Application

Cancer

Tuberculosis

Diabetes

Cardiovascular Diseases

Others

RNA-based Biopharmaceuticals Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA-based Biopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of RNA-based Biopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA-based Biopharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of RNA-based Biopharmaceuticals in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of RNA-based Biopharmaceuticals manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, RNA-based Biopharmaceuticals sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global RNA-based Biopharmaceuticals Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Therapeutics Major Manufacturers Table 3. Vaccines Major Manufacturers Table 4. Global RNA-based Biopharmaceuticals Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Cancer Major Manufacturers Table 6. Tuberculosis Major Manufacturers Table 7. Diabetes Major Manufacturers Table 8. Cardiovascular Diseases Major Manufacturers Table 9. Others Major Manufacturers Table 10. RNA-based Biopharmaceuticals Industry Trends Table 11. RNA-based Biopharmaceuticals Industry Drivers Table 12. RNA-based Biopharmaceuticals Industry Opportunities and Challenges Table 13. RNA-based Biopharmaceuticals Industry Restraints Table 14. Global RNA-based Biopharmaceuticals Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global RNA-based Biopharmaceuticals Revenue by Region (2021-2026) & (US$ Million) Table 16. Global RNA-based Biopharmaceuticals Revenue by Region (2027-2032) & (US$ Million) Table 17. Global RNA-based Biopharmaceuticals Revenue Market Share by Region (2021-2026) Table 18. Global RNA-based Biopharmaceuticals Revenue Market Share by Region (2027-2032) Table 19. Global RNA-based Biopharmaceuticals Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 20. Global RNA-based Biopharmaceuticals Sales by Region (2021-2026) & (k units) Table 21. Global RNA-based Biopharmaceuticals Sales by Region (2027-2032) & (k units) Table 22. Global RNA-based Biopharmaceuticals Sales Market Share by Region (2021-2026) Table 23. Global RNA-based Biopharmaceuticals Sales Market Share by Region (2027-2032) Table 24. Global RNA-based Biopharmaceuticals Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global RNA-based Biopharmaceuticals Revenue Market Share by Manufacturers (2021-2026) Table 26. Global RNA-based Biopharmaceuticals Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global RNA-based Biopharmaceuticals Sales Market Share by Manufacturers (2021-2026) Table 28. Global RNA-based Biopharmaceuticals Sales Price (US$/unit) of Manufacturers (2021-2026) Table 29. Global RNA-based Biopharmaceuticals Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global RNA-based Biopharmaceuticals Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global RNA-based Biopharmaceuticals Manufacturers, Product Type & Application Table 32. Global RNA-based Biopharmaceuticals Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global RNA-based Biopharmaceuticals by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global RNA-based Biopharmaceuticals Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global RNA-based Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 37. Global RNA-based Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 38. Global RNA-based Biopharmaceuticals Revenue Market Share by Type (2021-2026) Table 39. Global RNA-based Biopharmaceuticals Revenue Market Share by Type (2027-2032) Table 40. Global RNA-based Biopharmaceuticals Sales by Type 2021 VS 2025 VS 2032 (k units) Table 41. Global RNA-based Biopharmaceuticals Sales by Type (2021-2026) & (k units) Table 42. Global RNA-based Biopharmaceuticals Sales by Type (2027-2032) & (k units) Table 43. Global RNA-based Biopharmaceuticals Sales Market Share by Type (2021-2026) Table 44. Global RNA-based Biopharmaceuticals Sales Market Share by Type (2027-2032) Table 45. Global RNA-based Biopharmaceuticals Price by Type (2021-2026) & (US$/unit) Table 46. Global RNA-based Biopharmaceuticals Price by Type (2027-2032) & (US$/unit) Table 47. Global RNA-based Biopharmaceuticals Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global RNA-based Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 49. Global RNA-based Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 50. Global RNA-based Biopharmaceuticals Revenue Market Share by Application (2021-2026) Table 51. Global RNA-based Biopharmaceuticals Revenue Market Share by Application (2027-2032) Table 52. Global RNA-based Biopharmaceuticals Sales by Application 2021 VS 2025 VS 2032 (k units) Table 53. Global RNA-based Biopharmaceuticals Sales by Application (2021-2026) & (k units) Table 54. Global RNA-based Biopharmaceuticals Sales by Application (2027-2032) & (k units) Table 55. Global RNA-based Biopharmaceuticals Sales Market Share by Application (2021-2026) Table 56. Global RNA-based Biopharmaceuticals Sales Market Share by Application (2027-2032) Table 57. Global RNA-based Biopharmaceuticals Price by Application (2021-2026) & (US$/unit) Table 58. Global RNA-based Biopharmaceuticals Price by Application (2027-2032) & (US$/unit) Table 59. Roche Company Information Table 60. Roche Business Overview Table 61. Roche RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 62. Roche RNA-based Biopharmaceuticals Product Portfolio Table 63. Roche Recent Development Table 64. Pfizer Company Information Table 65. Pfizer Business Overview Table 66. Pfizer RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Pfizer RNA-based Biopharmaceuticals Product Portfolio Table 68. Pfizer Recent Development Table 69. Tekmira Company Information Table 70. Tekmira Business Overview Table 71. Tekmira RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Tekmira RNA-based Biopharmaceuticals Product Portfolio Table 73. Tekmira Recent Development Table 74. Silenseed Company Information Table 75. Silenseed Business Overview Table 76. Silenseed RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Silenseed RNA-based Biopharmaceuticals Product Portfolio Table 78. Silenseed Recent Development Table 79. Silence Therapeutics Company Information Table 80. Silence Therapeutics Business Overview Table 81. Silence Therapeutics RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Silence Therapeutics RNA-based Biopharmaceuticals Product Portfolio Table 83. Silence Therapeutics Recent Development Table 84. Senesco Company Information Table 85. Senesco Business Overview Table 86. Senesco RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Senesco RNA-based Biopharmaceuticals Product Portfolio Table 88. Senesco Recent Development Table 89. Sanofi-Aventis Company Information Table 90. Sanofi-Aventis Business Overview Table 91. Sanofi-Aventis RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Sanofi-Aventis RNA-based Biopharmaceuticals Product Portfolio Table 93. Sanofi-Aventis Recent Development Table 94. RXi Company Information Table 95. RXi Business Overview Table 96. RXi RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. RXi RNA-based Biopharmaceuticals Product Portfolio Table 98. RXi Recent Development Table 99. Quark Company Information Table 100. Quark Business Overview Table 101. Quark RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Quark RNA-based Biopharmaceuticals Product Portfolio Table 103. Quark Recent Development Table 104. Gradalis Company Information Table 105. Gradalis Business Overview Table 106. Gradalis RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Gradalis RNA-based Biopharmaceuticals Product Portfolio Table 108. Gradalis Recent Development Table 109. Dicerna Company Information Table 110. Dicerna Business Overview Table 111. Dicerna RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Dicerna RNA-based Biopharmaceuticals Product Portfolio Table 113. Dicerna Recent Development Table 114. Calimmune Inc Company Information Table 115. Calimmune Inc Business Overview Table 116. Calimmune Inc RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Calimmune Inc RNA-based Biopharmaceuticals Product Portfolio Table 118. Calimmune Inc Recent Development Table 119. Benitec Biopharma Company Information Table 120. Benitec Biopharma Business Overview Table 121. Benitec Biopharma RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Benitec Biopharma RNA-based Biopharmaceuticals Product Portfolio Table 123. Benitec Biopharma Recent Development Table 124. Arrowhead Pharmaceuticals Company Information Table 125. Arrowhead Pharmaceuticals Business Overview Table 126. Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Product Portfolio Table 128. Arrowhead Pharmaceuticals Recent Development Table 129. Alnylam Pharmaceuticals Company Information Table 130. Alnylam Pharmaceuticals Business Overview Table 131. Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Product Portfolio Table 133. Alnylam Pharmaceuticals Recent Development Table 134. Abbott Laboratories Company Information Table 135. Abbott Laboratories Business Overview Table 136. Abbott Laboratories RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Abbott Laboratories RNA-based Biopharmaceuticals Product Portfolio Table 138. Abbott Laboratories Recent Development Table 139. North America RNA-based Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 140. North America RNA-based Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 141. North America RNA-based Biopharmaceuticals Sales by Type (2021-2026) & (k units) Table 142. North America RNA-based Biopharmaceuticals Sales by Type (2027-2032) & (k units) Table 143. North America RNA-based Biopharmaceuticals Sales Price by Type (2021-2026) & (US$/unit) Table 144. North America RNA-based Biopharmaceuticals Sales Price by Type (2027-2032) & (US$/unit) Table 145. North America RNA-based Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 146. North America RNA-based Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 147. North America RNA-based Biopharmaceuticals Sales by Application (2021-2026) & (k units) Table 148. North America RNA-based Biopharmaceuticals Sales by Application (2027-2032) & (k units) Table 149. North America RNA-based Biopharmaceuticals Sales Price by Application (2021-2026) & (US$/unit) Table 150. North America RNA-based Biopharmaceuticals Sales Price by Application (2027-2032) & (US$/unit) Table 151. North America RNA-based Biopharmaceuticals Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 152. North America RNA-based Biopharmaceuticals Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 153. North America RNA-based Biopharmaceuticals Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 154. North America RNA-based Biopharmaceuticals Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 155. North America RNA-based Biopharmaceuticals Sales by Country (2021-2026) & (k units) Table 156. North America RNA-based Biopharmaceuticals Sales by Country (2027-2032) & (k units) Table 157. North America RNA-based Biopharmaceuticals Sales Price by Country (2021-2026) & (US$/unit) Table 158. North America RNA-based Biopharmaceuticals Sales Price by Country (2027-2032) & (US$/unit) Table 159. United States RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 160. Canada RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 161. Mexico RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 162. Europe RNA-based Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 163. Europe RNA-based Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 164. Europe RNA-based Biopharmaceuticals Sales by Type (2021-2026) & (k units) Table 165. Europe RNA-based Biopharmaceuticals Sales by Type (2027-2032) & (k units) Table 166. Europe RNA-based Biopharmaceuticals Sales Price by Type (2021-2026) & (US$/unit) Table 167. Europe RNA-based Biopharmaceuticals Sales Price by Type (2027-2032) & (US$/unit) Table 168. Europe RNA-based Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 169. Europe RNA-based Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 170. Europe RNA-based Biopharmaceuticals Sales by Application (2021-2026) & (k units) Table 171. Europe RNA-based Biopharmaceuticals Sales by Application (2027-2032) & (k units) Table 172. Europe RNA-based Biopharmaceuticals Sales Price by Application (2021-2026) & (US$/unit) Table 173. Europe RNA-based Biopharmaceuticals Sales Price by Application (2027-2032) & (US$/unit) Table 174. Europe RNA-based Biopharmaceuticals Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 175. Europe RNA-based Biopharmaceuticals Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 176. Europe RNA-based Biopharmaceuticals Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 177. Europe RNA-based Biopharmaceuticals Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 178. Europe RNA-based Biopharmaceuticals Sales by Country (2021-2026) & (k units) Table 179. Europe RNA-based Biopharmaceuticals Sales by Country (2027-2032) & (k units) Table 180. Europe RNA-based Biopharmaceuticals Sales Price by Country (2021-2026) & (US$/unit) Table 181. Europe RNA-based Biopharmaceuticals Sales Price by Country (2027-2032) & (US$/unit) Table 182. Germany RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 183. France RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 184. U.K. RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 185. Italy RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 186. Russia RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 187. Spain RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 188. Netherlands RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 189. Switzerland RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 190. Sweden RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 191. Poland RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 192. China RNA-based Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 193. China RNA-based Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 194. China RNA-based Biopharmaceuticals Sales by Type (2021-2026) & (k units) Table 195. China RNA-based Biopharmaceuticals Sales by Type (2027-2032) & (k units) Table 196. China RNA-based Biopharmaceuticals Sales Price by Type (2021-2026) & (US$/unit) Table 197. China RNA-based Biopharmaceuticals Sales Price by Type (2027-2032) & (US$/unit) Table 198. China RNA-based Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 199. China RNA-based Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 200. China RNA-based Biopharmaceuticals Sales by Application (2021-2026) & (k units) Table 201. China RNA-based Biopharmaceuticals Sales by Application (2027-2032) & (k units) Table 202. China RNA-based Biopharmaceuticals Sales Price by Application (2021-2026) & (US$/unit) Table 203. China RNA-based Biopharmaceuticals Sales Price by Application (2027-2032) & (US$/unit) Table 204. Asia RNA-based Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 205. Asia RNA-based Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 206. Asia RNA-based Biopharmaceuticals Sales by Type (2021-2026) & (k units) Table 207. Asia RNA-based Biopharmaceuticals Sales by Type (2027-2032) & (k units) Table 208. Asia RNA-based Biopharmaceuticals Sales Price by Type (2021-2026) & (US$/unit) Table 209. Asia RNA-based Biopharmaceuticals Sales Price by Type (2027-2032) & (US$/unit) Table 210. Asia RNA-based Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 211. Asia RNA-based Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 212. Asia RNA-based Biopharmaceuticals Sales by Application (2021-2026) & (k units) Table 213. Asia RNA-based Biopharmaceuticals Sales by Application (2027-2032) & (k units) Table 214. Asia RNA-based Biopharmaceuticals Sales Price by Application (2021-2026) & (US$/unit) Table 215. Asia RNA-based Biopharmaceuticals Sales Price by Application (2027-2032) & (US$/unit) Table 216. Asia RNA-based Biopharmaceuticals Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 217. Asia RNA-based Biopharmaceuticals Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 218. Asia RNA-based Biopharmaceuticals Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 219. Asia RNA-based Biopharmaceuticals Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 220. Asia RNA-based Biopharmaceuticals Sales by Country (2021-2026) & (k units) Table 221. Asia RNA-based Biopharmaceuticals Sales by Country (2027-2032) & (k units) Table 222. Asia RNA-based Biopharmaceuticals Sales Price by Country (2021-2026) & (US$/unit) Table 223. Asia RNA-based Biopharmaceuticals Sales Price by Country (2027-2032) & (US$/unit) Table 224. Japan RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 225. South Korea RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 226. India RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 227. Australia RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 228. Taiwan RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 229. Southeast Asia RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 230. SAMEA RNA-based Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 231. SAMEA RNA-based Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 232. SAMEA RNA-based Biopharmaceuticals Sales by Type (2021-2026) & (k units) Table 233. SAMEA RNA-based Biopharmaceuticals Sales by Type (2027-2032) & (k units) Table 234. SAMEA RNA-based Biopharmaceuticals Sales Price by Type (2021-2026) & (US$/unit) Table 235. SAMEA RNA-based Biopharmaceuticals Sales Price by Type (2027-2032) & (US$/unit) Table 236. SAMEA RNA-based Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 237. SAMEA RNA-based Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 238. SAMEA RNA-based Biopharmaceuticals Sales by Application (2021-2026) & (k units) Table 239. SAMEA RNA-based Biopharmaceuticals Sales by Application (2027-2032) & (k units) Table 240. SAMEA RNA-based Biopharmaceuticals Sales Price by Application (2021-2026) & (US$/unit) Table 241. SAMEA RNA-based Biopharmaceuticals Sales Price by Application (2027-2032) & (US$/unit) Table 242. SAMEA RNA-based Biopharmaceuticals Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 243. SAMEA RNA-based Biopharmaceuticals Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 244. SAMEA RNA-based Biopharmaceuticals Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 245. SAMEA RNA-based Biopharmaceuticals Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 246. SAMEA RNA-based Biopharmaceuticals Sales by Country (2021-2026) & (k units) Table 247. SAMEA RNA-based Biopharmaceuticals Sales by Country (2027-2032) & (k units) Table 248. SAMEA RNA-based Biopharmaceuticals Sales Price by Country (2021-2026) & (US$/unit) Table 249. SAMEA RNA-based Biopharmaceuticals Sales Price by Country (2027-2032) & (US$/unit) Table 250. Brazil RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 251. Argentina RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 252. Chile RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 253. Colombia RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 254. Peru RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 255. Saudi Arabia RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 256. Israel RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 257. UAE RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 258. Turkey RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 259. Iran RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 260. Egypt RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Table 261. Key Raw Materials Table 262. Raw Materials Key Suppliers Table 263. RNA-based Biopharmaceuticals Distributors List Table 264. RNA-based Biopharmaceuticals Customers List Table 265. Research Programs/Design for This Report Table 266. Authors List of This Report Table 267. Secondary Sources Table 268. Primary Sources List of Figures Figure 1. RNA-based Biopharmaceuticals Image Figure 2. Global RNA-based Biopharmaceuticals Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global RNA-based Biopharmaceuticals Market Size Share 2021 VS 2025 VS 2032 Figure 4. Therapeutics Image Figure 5. Vaccines Image Figure 6. Global RNA-based Biopharmaceuticals Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global RNA-based Biopharmaceuticals Market Size Share 2021 VS 2025 VS 2032 Figure 8. Cancer Image Figure 9. Tuberculosis Image Figure 10. Diabetes Image Figure 11. Cardiovascular Diseases Image Figure 12. Others Image Figure 13. Global RNA-based Biopharmaceuticals Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global RNA-based Biopharmaceuticals Revenue (2021-2032) & (US$ Million) Figure 15. Global RNA-based Biopharmaceuticals Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global RNA-based Biopharmaceuticals Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global RNA-based Biopharmaceuticals Revenue Market Share by Region (2021-2032) Figure 18. Global RNA-based Biopharmaceuticals Sales (2021-2032) & (k units) Figure 19. Global RNA-based Biopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 20. Global RNA-based Biopharmaceuticals Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico RNA-based Biopharmaceuticals Sales YoY (2021-2032) & (k units) Figure 22. Europe RNA-based Biopharmaceuticals Sales YoY (2021-2032) & (k units) Figure 23. China RNA-based Biopharmaceuticals Sales YoY (2021-2032) & (k units) Figure 24. Asia (Excluding China) RNA-based Biopharmaceuticals Sales YoY (2021-2032) & (k units) Figure 25. South America, Middle East and Africa RNA-based Biopharmaceuticals Sales YoY (2021-2032) & (k units) Figure 26. Global RNA-based Biopharmaceuticals Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global RNA-based Biopharmaceuticals Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global RNA-based Biopharmaceuticals Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global RNA-based Biopharmaceuticals Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global RNA-based Biopharmaceuticals Revenue Market Share by Type (2021-2032) Figure 32. Global RNA-based Biopharmaceuticals Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 33. Global RNA-based Biopharmaceuticals Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global RNA-based Biopharmaceuticals Sales Market Share by Type (2021-2032) Figure 35. Global RNA-based Biopharmaceuticals Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global RNA-based Biopharmaceuticals Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global RNA-based Biopharmaceuticals Revenue Market Share by Application (2021-2032) Figure 38. Global RNA-based Biopharmaceuticals Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 39. Global RNA-based Biopharmaceuticals Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global RNA-based Biopharmaceuticals Sales Market Share by Application (2021-2032) Figure 41. North America RNA-based Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 42. North America RNA-based Biopharmaceuticals Sales Share by Type (2021-2032) Figure 43. North America RNA-based Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 44. North America RNA-based Biopharmaceuticals Sales Share by Application (2021-2032) Figure 45. North America RNA-based Biopharmaceuticals Revenue Share by Country (2021-2032) Figure 46. North America RNA-based Biopharmaceuticals Sales Share by Country (2021-2032) Figure 47. Europe RNA-based Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 48. Europe RNA-based Biopharmaceuticals Sales Share by Type (2021-2032) Figure 49. Europe RNA-based Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 50. Europe RNA-based Biopharmaceuticals Sales Share by Application (2021-2032) Figure 51. Europe RNA-based Biopharmaceuticals Revenue Share by Country (2021-2032) Figure 52. Europe RNA-based Biopharmaceuticals Sales Share by Country (2021-2032) Figure 53. China RNA-based Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 54. China RNA-based Biopharmaceuticals Sales Share by Type (2021-2032) Figure 55. China RNA-based Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 56. China RNA-based Biopharmaceuticals Sales Share by Application (2021-2032) Figure 57. Asia RNA-based Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 58. Asia RNA-based Biopharmaceuticals Sales Share by Type (2021-2032) Figure 59. Asia RNA-based Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 60. Asia RNA-based Biopharmaceuticals Sales Share by Application (2021-2032) Figure 61. Asia RNA-based Biopharmaceuticals Revenue Share by Country (2021-2032) Figure 62. Asia RNA-based Biopharmaceuticals Sales Share by Country (2021-2032) Figure 63. SAMEA RNA-based Biopharmaceuticals Revenue Share by Type (2021-2032) Figure 64. SAMEA RNA-based Biopharmaceuticals Sales Share by Type (2021-2032) Figure 65. SAMEA RNA-based Biopharmaceuticals Revenue Share by Application (2021-2032) Figure 66. SAMEA RNA-based Biopharmaceuticals Sales Share by Application (2021-2032) Figure 67. SAMEA RNA-based Biopharmaceuticals Revenue Share by Country (2021-2032) Figure 68. SAMEA RNA-based Biopharmaceuticals Sales Share by Country (2021-2032) Figure 69. RNA-based Biopharmaceuticals Value Chain Figure 70. Manufacturing Cost Structure Figure 71. RNA-based Biopharmaceuticals Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Therapeutics
  • Vaccines
Applications
  • Cancer
  • Tuberculosis
  • Diabetes
  • Cardiovascular Diseases
  • Others
Companies covered
  • Roche
  • Pfizer
  • Tekmira
  • Silenseed
  • Silence Therapeutics
  • Senesco
  • Sanofi-Aventis
  • RXi
  • Quark
  • Gradalis
  • Dicerna
  • Calimmune Inc
  • Benitec Biopharma
  • Arrowhead Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 RNA-based Biopharmaceuticals Market by Type
  3. 1.2.1 Global RNA-based Biopharmaceuticals Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Therapeutics
  5. 1.2.3 Vaccines
  6. 1.3 RNA-based Biopharmaceuticals Market by Application
  7. 1.3.1 Global RNA-based Biopharmaceuticals Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Cancer
  9. 1.3.3 Tuberculosis
  10. 1.3.4 Diabetes
  11. 1.3.5 Cardiovascular Diseases
  12. 1.3.6 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 RNA-based Biopharmaceuticals Market Dynamics
  1. 2.1 RNA-based Biopharmaceuticals Industry Trends
  2. 2.2 RNA-based Biopharmaceuticals Industry Drivers
  3. 2.3 RNA-based Biopharmaceuticals Industry Opportunities and Challenges
  4. 2.4 RNA-based Biopharmaceuticals Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global RNA-based Biopharmaceuticals Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global RNA-based Biopharmaceuticals Revenue by Region
  3. 3.2.1 Global RNA-based Biopharmaceuticals Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global RNA-based Biopharmaceuticals Revenue by Region (2021-2026)
  5. 3.2.3 Global RNA-based Biopharmaceuticals Revenue by Region (2027-2032)
  6. 3.2.4 Global RNA-based Biopharmaceuticals Revenue Market Share by Region (2021-2032)
  7. 3.3 Global RNA-based Biopharmaceuticals Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global RNA-based Biopharmaceuticals Sales by Region
  9. 3.4.1 Global RNA-based Biopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global RNA-based Biopharmaceuticals Sales by Region (2021-2026)
  11. 3.4.3 Global RNA-based Biopharmaceuticals Sales by Region (2027-2032)
  12. 3.4.4 Global RNA-based Biopharmaceuticals Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global RNA-based Biopharmaceuticals Revenue by Manufacturers
  2. 4.1.1 Global RNA-based Biopharmaceuticals Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global RNA-based Biopharmaceuticals Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global RNA-based Biopharmaceuticals Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global RNA-based Biopharmaceuticals Sales by Manufacturers
  6. 4.2.1 Global RNA-based Biopharmaceuticals Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global RNA-based Biopharmaceuticals Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global RNA-based Biopharmaceuticals Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global RNA-based Biopharmaceuticals Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global RNA-based Biopharmaceuticals Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global RNA-based Biopharmaceuticals Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global RNA-based Biopharmaceuticals Manufacturers, Product Type & Application
  13. 4.7 Global RNA-based Biopharmaceuticals Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global RNA-based Biopharmaceuticals Market CR5 and HHI
  16. 4.8.2 2025 RNA-based Biopharmaceuticals Tier 1, Tier 2, and Tier 3
5 RNA-based Biopharmaceuticals Market by Type
  1. 5.1 Global RNA-based Biopharmaceuticals Revenue by Type
  2. 5.1.1 Global RNA-based Biopharmaceuticals Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global RNA-based Biopharmaceuticals Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global RNA-based Biopharmaceuticals Revenue Market Share by Type (2021-2032)
  5. 5.2 Global RNA-based Biopharmaceuticals Sales by Type
  6. 5.2.1 Global RNA-based Biopharmaceuticals Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global RNA-based Biopharmaceuticals Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global RNA-based Biopharmaceuticals Sales Market Share by Type (2021-2032)
  9. 5.3 Global RNA-based Biopharmaceuticals Price by Type
6 RNA-based Biopharmaceuticals Market by Application
  1. 6.1 Global RNA-based Biopharmaceuticals Revenue by Application
  2. 6.1.1 Global RNA-based Biopharmaceuticals Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global RNA-based Biopharmaceuticals Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global RNA-based Biopharmaceuticals Revenue Market Share by Application (2021-2032)
  5. 6.2 Global RNA-based Biopharmaceuticals Sales by Application
  6. 6.2.1 Global RNA-based Biopharmaceuticals Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global RNA-based Biopharmaceuticals Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global RNA-based Biopharmaceuticals Sales Market Share by Application (2021-2032)
  9. 6.3 Global RNA-based Biopharmaceuticals Price by Application
7 Company Profiles
  1. 7.1 Roche
  2. 7.1.1 Roche Company Information
  3. 7.1.2 Roche Business Overview
  4. 7.1.3 Roche RNA-based Biopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Roche RNA-based Biopharmaceuticals Product Portfolio
  6. 7.1.5 Roche Recent Developments
  7. 7.2 Pfizer
  8. 7.2.1 Pfizer Company Information
  9. 7.2.2 Pfizer Business Overview
  10. 7.2.3 Pfizer RNA-based Biopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer RNA-based Biopharmaceuticals Product Portfolio
  12. 7.2.5 Pfizer Recent Developments
  13. 7.3 Tekmira
  14. 7.3.1 Tekmira Company Information
  15. 7.3.2 Tekmira Business Overview
  16. 7.3.3 Tekmira RNA-based Biopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Tekmira RNA-based Biopharmaceuticals Product Portfolio
  18. 7.3.5 Tekmira Recent Developments
  19. 7.4 Silenseed
  20. 7.4.1 Silenseed Company Information
  21. 7.4.2 Silenseed Business Overview
  22. 7.4.3 Silenseed RNA-based Biopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Silenseed RNA-based Biopharmaceuticals Product Portfolio
  24. 7.4.5 Silenseed Recent Developments
  25. 7.5 Silence Therapeutics
  26. 7.5.1 Silence Therapeutics Company Information
  27. 7.5.2 Silence Therapeutics Business Overview
  28. 7.5.3 Silence Therapeutics RNA-based Biopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Silence Therapeutics RNA-based Biopharmaceuticals Product Portfolio
  30. 7.5.5 Silence Therapeutics Recent Developments
  31. 7.6 Senesco
  32. 7.6.1 Senesco Company Information
  33. 7.6.2 Senesco Business Overview
  34. 7.6.3 Senesco RNA-based Biopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Senesco RNA-based Biopharmaceuticals Product Portfolio
  36. 7.6.5 Senesco Recent Developments
  37. 7.7 Sanofi-Aventis
  38. 7.7.1 Sanofi-Aventis Company Information
  39. 7.7.2 Sanofi-Aventis Business Overview
  40. 7.7.3 Sanofi-Aventis RNA-based Biopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Sanofi-Aventis RNA-based Biopharmaceuticals Product Portfolio
  42. 7.7.5 Sanofi-Aventis Recent Developments
  43. 7.8 RXi
  44. 7.8.1 RXi Company Information
  45. 7.8.2 RXi Business Overview
  46. 7.8.3 RXi RNA-based Biopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 RXi RNA-based Biopharmaceuticals Product Portfolio
  48. 7.8.5 RXi Recent Developments
  49. 7.9 Quark
  50. 7.9.1 Quark Company Information
  51. 7.9.2 Quark Business Overview
  52. 7.9.3 Quark RNA-based Biopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Quark RNA-based Biopharmaceuticals Product Portfolio
  54. 7.9.5 Quark Recent Developments
  55. 7.10 Gradalis
  56. 7.10.1 Gradalis Company Information
  57. 7.10.2 Gradalis Business Overview
  58. 7.10.3 Gradalis RNA-based Biopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Gradalis RNA-based Biopharmaceuticals Product Portfolio
  60. 7.10.5 Gradalis Recent Developments
  61. 7.11 Dicerna
  62. 7.11.1 Dicerna Company Information
  63. 7.11.2 Dicerna Business Overview
  64. 7.11.3 Dicerna RNA-based Biopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Dicerna RNA-based Biopharmaceuticals Product Portfolio
  66. 7.11.5 Dicerna Recent Developments
  67. 7.12 Calimmune Inc
  68. 7.12.1 Calimmune Inc Company Information
  69. 7.12.2 Calimmune Inc Business Overview
  70. 7.12.3 Calimmune Inc RNA-based Biopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Calimmune Inc RNA-based Biopharmaceuticals Product Portfolio
  72. 7.12.5 Calimmune Inc Recent Developments
  73. 7.13 Benitec Biopharma
  74. 7.13.1 Benitec Biopharma Company Information
  75. 7.13.2 Benitec Biopharma Business Overview
  76. 7.13.3 Benitec Biopharma RNA-based Biopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Benitec Biopharma RNA-based Biopharmaceuticals Product Portfolio
  78. 7.13.5 Benitec Biopharma Recent Developments
  79. 7.14 Arrowhead Pharmaceuticals
  80. 7.14.1 Arrowhead Pharmaceuticals Company Information
  81. 7.14.2 Arrowhead Pharmaceuticals Business Overview
  82. 7.14.3 Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Product Portfolio
  84. 7.14.5 Arrowhead Pharmaceuticals Recent Developments
  85. 7.15 Alnylam Pharmaceuticals
  86. 7.15.1 Alnylam Pharmaceuticals Company Information
  87. 7.15.2 Alnylam Pharmaceuticals Business Overview
  88. 7.15.3 Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Product Portfolio
  90. 7.15.5 Alnylam Pharmaceuticals Recent Developments
  91. 7.16 Abbott Laboratories
  92. 7.16.1 Abbott Laboratories Company Information
  93. 7.16.2 Abbott Laboratories Business Overview
  94. 7.16.3 Abbott Laboratories RNA-based Biopharmaceuticals Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Abbott Laboratories RNA-based Biopharmaceuticals Product Portfolio
  96. 7.16.5 Abbott Laboratories Recent Developments
8 North America
  1. 8.1 North America RNA-based Biopharmaceuticals Market Size by Type
  2. 8.1.1 North America RNA-based Biopharmaceuticals Revenue by Type (2021-2032)
  3. 8.1.2 North America RNA-based Biopharmaceuticals Sales by Type (2021-2032)
  4. 8.1.3 North America RNA-based Biopharmaceuticals Price by Type (2021-2032)
  5. 8.2 North America RNA-based Biopharmaceuticals Market Size by Application
  6. 8.2.1 North America RNA-based Biopharmaceuticals Revenue by Application (2021-2032)
  7. 8.2.2 North America RNA-based Biopharmaceuticals Sales by Application (2021-2032)
  8. 8.2.3 North America RNA-based Biopharmaceuticals Price by Application (2021-2032)
  9. 8.3 North America RNA-based Biopharmaceuticals Market Size by Country
  10. 8.3.1 North America RNA-based Biopharmaceuticals Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America RNA-based Biopharmaceuticals Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America RNA-based Biopharmaceuticals Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe RNA-based Biopharmaceuticals Market Size by Type
  2. 9.1.1 Europe RNA-based Biopharmaceuticals Revenue by Type (2021-2032)
  3. 9.1.2 Europe RNA-based Biopharmaceuticals Sales by Type (2021-2032)
  4. 9.1.3 Europe RNA-based Biopharmaceuticals Price by Type (2021-2032)
  5. 9.2 Europe RNA-based Biopharmaceuticals Market Size by Application
  6. 9.2.1 Europe RNA-based Biopharmaceuticals Revenue by Application (2021-2032)
  7. 9.2.2 Europe RNA-based Biopharmaceuticals Sales by Application (2021-2032)
  8. 9.2.3 Europe RNA-based Biopharmaceuticals Price by Application (2021-2032)
  9. 9.3 Europe RNA-based Biopharmaceuticals Market Size by Country
  10. 9.3.1 Europe RNA-based Biopharmaceuticals Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe RNA-based Biopharmaceuticals Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe RNA-based Biopharmaceuticals Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China RNA-based Biopharmaceuticals Market Size by Type
  2. 10.1.1 China RNA-based Biopharmaceuticals Revenue by Type (2021-2032)
  3. 10.1.2 China RNA-based Biopharmaceuticals Sales by Type (2021-2032)
  4. 10.1.3 China RNA-based Biopharmaceuticals Price by Type (2021-2032)
  5. 10.2 China RNA-based Biopharmaceuticals Market Size by Application
  6. 10.2.1 China RNA-based Biopharmaceuticals Revenue by Application (2021-2032)
  7. 10.2.2 China RNA-based Biopharmaceuticals Sales by Application (2021-2032)
  8. 10.2.3 China RNA-based Biopharmaceuticals Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia RNA-based Biopharmaceuticals Market Size by Type
  2. 11.1.1 Asia RNA-based Biopharmaceuticals Revenue by Type (2021-2032)
  3. 11.1.2 Asia RNA-based Biopharmaceuticals Sales by Type (2021-2032)
  4. 11.1.3 Asia RNA-based Biopharmaceuticals Price by Type (2021-2032)
  5. 11.2 Asia RNA-based Biopharmaceuticals Market Size by Application
  6. 11.2.1 Asia RNA-based Biopharmaceuticals Revenue by Application (2021-2032)
  7. 11.2.2 Asia RNA-based Biopharmaceuticals Sales by Application (2021-2032)
  8. 11.2.3 Asia RNA-based Biopharmaceuticals Price by Application (2021-2032)
  9. 11.3 Asia RNA-based Biopharmaceuticals Market Size by Country
  10. 11.3.1 Asia RNA-based Biopharmaceuticals Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia RNA-based Biopharmaceuticals Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia RNA-based Biopharmaceuticals Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA RNA-based Biopharmaceuticals Market Size by Type
  2. 12.1.1 SAMEA RNA-based Biopharmaceuticals Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA RNA-based Biopharmaceuticals Sales by Type (2021-2032)
  4. 12.1.3 SAMEA RNA-based Biopharmaceuticals Price by Type (2021-2032)
  5. 12.2 SAMEA RNA-based Biopharmaceuticals Market Size by Application
  6. 12.2.1 SAMEA RNA-based Biopharmaceuticals Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA RNA-based Biopharmaceuticals Sales by Application (2021-2032)
  8. 12.2.3 SAMEA RNA-based Biopharmaceuticals Price by Application (2021-2032)
  9. 12.3 SAMEA RNA-based Biopharmaceuticals Market Size by Country
  10. 12.3.1 SAMEA RNA-based Biopharmaceuticals Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA RNA-based Biopharmaceuticals Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA RNA-based Biopharmaceuticals Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 RNA-based Biopharmaceuticals Value Chain Analysis
  2. 13.1.1 RNA-based Biopharmaceuticals Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 RNA-based Biopharmaceuticals Production Mode & Process
  6. 13.2 RNA-based Biopharmaceuticals Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 RNA-based Biopharmaceuticals Distributors
  9. 13.2.3 RNA-based Biopharmaceuticals Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst